Company Overview: OncoCyte

Industry News

26 Jun

OncoCyte Corporation Added to Russell 3000® Index and Russell 2000® Index

ALAMEDA, Calif., June 26, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests for the early detection of cancer, has been added to the broad U.S. market Russell 3000® Index and the small-cap Russell 2000® Index as part of Russell Investments’...

Read more

29 Jan


OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company believes that better and earlier detection of cancer through liquid biopsies will: Improve patient outcomes Increase the life expectancy of cancer patients Significantly reduce health care...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets


Follow this blog

Get every new post delivered right to your inbox.

Email address